This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and a Kybella injection. Each patient will have a treatment and a control site.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
34
Injection into the cutaneous Neurofibromas lesion
Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
Wellman Center for Photomedicine, Massachusetts General Hospital
Boston, Massachusetts, United States
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Device based treatment will be considered tolerable if \<40% of participants treated have a \>grade 2 adverse event (AE). A grade 2 AE is defined as an event that requires treatment.
Time frame: 3 months after treatment
Patient Report Outcomes
Using questionnaires we will determine the patients reported outcomes
Time frame: For the 12 months after treatment
Clinician Reported Outcomes
Using questionnaires we will determine the clinicians reported outcomes
Time frame: For the 12 months after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.